{"product_id":"angiodynamics-swot-analysis","title":"AngioDynamics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAngioDynamics leverages its innovative technologies in minimally invasive treatments, a significant strength in a growing healthcare market. However, navigating regulatory hurdles and intense competition presents key challenges.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind AngioDynamics' strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong MedTech Segment Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioDynamics' MedTech segment is a significant growth engine, showcasing impressive performance.  In Q4 of fiscal year 2025, net sales for this segment surged by 22.0% compared to the previous year. This strong momentum carried through the entire fiscal year 2025, with a notable 19.5% increase in net sales.\u003c\/p\u003e\n\u003cp\u003eThe success of key platforms like Auryon, AlphaVac, and NanoKnife underscores the market's positive reception to AngioDynamics' innovative technologies. This segment is not just growing; it's becoming a cornerstone of the company's financial health, accounting for 45% of total sales in the fourth quarter of fiscal year 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative and Focused Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioDynamics boasts a strong portfolio of innovative medical devices designed for minimally invasive procedures. Their focus is particularly sharp in areas like peripheral vascular disease, oncology, and managing blood clots, addressing significant unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eKey products such as the Auryon atherectomy system, the AlphaVac mechanical thrombectomy device, and the NanoKnife system for irreversible electroporation highlight this specialized expertise. These offerings are designed to tackle complex medical challenges in growing markets.\u003c\/p\u003e\n\u003cp\u003eThis concentrated approach allows AngioDynamics to cultivate deep knowledge and drive innovation within these specific therapeutic fields, positioning them as a leader in targeted treatment solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecent Regulatory Clearances and Clinical Validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics has made significant strides in regulatory approvals, including FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation in December 2024. This, along with the April 2024 clearance for the AlphaVac F1885 System targeting pulmonary embolism, demonstrates a strong pipeline and market readiness.\u003c\/p\u003e\n\u003cp\u003eFurthermore, ongoing clinical trials such as AMBITION BTK for Auryon and RECOVER-AV for AlphaVac are actively generating robust clinical data. This evidence is crucial for validating product efficacy and safety, which in turn is expected to accelerate market adoption and strengthen the company's competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Transformation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAngioDynamics has successfully executed a strategic business transformation, a key strength that reshapes its market focus. This involved divesting non-core assets such as the Dialysis, BioSentry, PICC, and Midline businesses, alongside discontinuing certain older products. \u003c\/p\u003e\n\u003cp\u003eThis strategic streamlining is designed to concentrate the company's resources and investments into its higher-growth, higher-margin MedTech markets. This repositioning has significantly broadened AngioDynamics' addressable market opportunity, expanding it from an estimated $3 billion in 2021 to over $10 billion. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Divestitures:\u003c\/strong\u003e Shedding non-core assets like Dialysis and BioSentry to sharpen focus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Portfolio Optimization:\u003c\/strong\u003e Discontinuing legacy products to streamline operations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Market Focus:\u003c\/strong\u003e Concentrating resources on high-growth MedTech segments.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpanded Addressable Market:\u003c\/strong\u003e Growing the opportunity from $3 billion in 2021 to over $10 billion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Financial Performance and Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAngioDynamics demonstrated robust financial performance in Q4 FY2025, marked by a 12.7% surge in net sales. This growth, coupled with a notable increase in adjusted EBITDA, highlights the company's enhanced profitability and operational efficiency.\u003c\/p\u003e\n\u003cp\u003eThe company's cash flow generation was particularly strong, with $16.2 million in free cash flow reported for Q4 FY2025. This positive cash flow, alongside ending the fiscal year with $55.9 million in cash and cash equivalents, solidifies AngioDynamics' financial health and capacity for future initiatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eNet Sales Growth:\u003c\/strong\u003e 12.7% increase in Q4 FY2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdjusted EBITDA:\u003c\/strong\u003e Significant improvement reported.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFree Cash Flow:\u003c\/strong\u003e $16.2 million generated in Q4 FY2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Position:\u003c\/strong\u003e $55.9 million in cash and cash equivalents at year-end FY2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative MedTech Fuels 22% Sales Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics possesses a strong and growing MedTech portfolio, evident in its Q4 FY2025 net sales increase of 22.0%. Key innovative products like Auryon, AlphaVac, and NanoKnife are driving this expansion, with the MedTech segment now representing 45% of total sales. This focus on specialized, minimally invasive solutions for peripheral vascular disease, oncology, and thrombectomy addresses significant market needs.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of AngioDynamics’s internal and external business factors, highlighting its strengths in minimally invasive technologies and opportunities in market expansion, while also addressing weaknesses in product diversification and threats from competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable SWOT analysis for AngioDynamics, pinpointing strengths and opportunities to leverage for pain point relief in the medical device market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Overall Net Loss\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite impressive revenue gains in its MedTech sector and a healthier adjusted EBITDA, AngioDynamics is still facing challenges with its overall net loss on a GAAP basis. The company reported a GAAP net loss of $6.1 million, or $0.15 per share, in the fourth quarter of fiscal 2025. This persistent net loss highlights that while operational improvements are evident, achieving consistent GAAP profitability remains an ongoing objective for the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Tariffs on Gross Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioDynamics has experienced negative impacts on its gross margin due to tariffs. For instance, in the fourth quarter of fiscal year 2025, these tariffs resulted in a $1.6 million increase in the cost of goods sold, directly reducing the reported gross margin.\u003c\/p\u003e\n\u003cp\u003eAlthough the company offers figures that exclude these tariff-related costs, these external pressures on expenses can still influence overall profitability. This necessitates strategic considerations for AngioDynamics, potentially involving adjustments to pricing strategies or the optimization of its supply chain to mitigate such impacts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUneven Segment Growth Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics faces a significant challenge with uneven segment growth. While its MedTech segment is a strong performer, the Med Device segment is lagging considerably. For the full fiscal year 2025, Med Device sales saw a modest increase of just 0.8%.\u003c\/p\u003e\n\u003cp\u003eLooking ahead, the outlook for the Med Device segment remains subdued, with projections indicating sales will stay roughly flat in fiscal year 2026. This disparity highlights a growing dependence on the MedTech portfolio for the company's overall expansion, suggesting the Med Device segment is not a substantial driver of top-line growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolatility in International Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAngioDynamics faces challenges with international sales volatility. For instance, in the first quarter of fiscal year 2025, international net sales experienced a notable decline of 25.4% when compared to the same period in the previous year. This significant drop was largely due to the timing of order placements in overseas markets.\u003c\/p\u003e\n\u003cp\u003eThis fluctuation in international revenue streams can hinder AngioDynamics' ability to achieve predictable global sales figures. It underscores the company's exposure to external factors impacting its overseas business.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eInternational Sales Decline:\u003c\/strong\u003e Q1 FY2025 international net sales decreased by 25.4% year-over-year.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrder Timing Impact:\u003c\/strong\u003e The primary driver for this decrease was attributed to the timing of international orders.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Predictability:\u003c\/strong\u003e Such volatility can make consistent global revenue generation more difficult.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Sensitivities:\u003c\/strong\u003e This highlights potential sensitivities to regional economic conditions or distribution network performance outside the U.S.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOngoing Manufacturing Transition Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAngioDynamics faces risks associated with its ongoing manufacturing transition, a strategic move to lower overhead and boost margins. This shift, while beneficial long-term, introduces immediate operational hurdles and potential disruptions. For instance, the company has previously noted that supply chain complexities and the integration of new processes can impact production timelines and costs, with specific figures often detailed in quarterly earnings calls regarding inventory adjustments or one-time transition expenses.\u003c\/p\u003e\n\u003cp\u003eThe success of this manufacturing overhaul is paramount for AngioDynamics to achieve its projected efficiency gains and cost savings. Any missteps in managing this transition, such as delays in production ramp-up or unforeseen quality control issues at new facilities, could negatively affect revenue and profitability in the short to medium term. Investors closely monitor these operational metrics, looking for evidence of smooth execution and the realization of anticipated cost reductions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Complexities:\u003c\/strong\u003e The transition can lead to temporary inefficiencies, impacting production output and delivery schedules.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisruption Risks:\u003c\/strong\u003e Unforeseen issues in supply chains or manufacturing processes could cause product shortages or delays.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssociated Costs:\u003c\/strong\u003e Initial setup, retraining, and potential write-offs of old facilities contribute to transition expenses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngioDynamics Faces Persistent Losses, Tariff Woes, and Slow Segment Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics continues to grapple with a persistent GAAP net loss, reporting $6.1 million in Q4 FY2025, indicating ongoing challenges in achieving overall profitability despite operational improvements. Tariffs have also negatively impacted gross margins, increasing the cost of goods sold by $1.6 million in Q4 FY2025, a direct hit to profitability that necessitates careful cost management and pricing strategies.\u003c\/p\u003e\n\u003cp\u003eThe company's Med Device segment shows considerable weakness, with sales growing only 0.8% in FY2025 and projected to remain flat in FY2026, creating an over-reliance on the MedTech segment for growth. Furthermore, international sales experienced a sharp 25.4% decline in Q1 FY2025 due to order timing, highlighting volatility and potential sensitivities in global markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeakness\u003c\/td\u003e\n\u003ctd\u003eFY2025 Impact\u003c\/td\u003e\n\u003ctd\u003eOutlook\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Net Loss\u003c\/td\u003e\n\u003ctd\u003e$6.1 million (Q4 FY2025)\u003c\/td\u003e\n\u003ctd\u003ePersistent challenge to achieve consistent profitability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff Impact on Gross Margin\u003c\/td\u003e\n\u003ctd\u003e+$1.6 million COGS (Q4 FY2025)\u003c\/td\u003e\n\u003ctd\u003eRequires strategic adjustments to pricing and supply chain.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Device Segment Growth\u003c\/td\u003e\n\u003ctd\u003e0.8% (FY2025)\u003c\/td\u003e\n\u003ctd\u003eProjected flat sales in FY2026, limiting top-line contribution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Sales Volatility\u003c\/td\u003e\n\u003ctd\u003e-25.4% (Q1 FY2025)\u003c\/td\u003e\n\u003ctd\u003eImpacted by order timing, affecting revenue predictability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAngioDynamics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real document you'll receive—professional, structured, and ready to use. It showcases the comprehensive AngioDynamics SWOT analysis, detailing its Strengths, Weaknesses, Opportunities, and Threats. You're seeing exactly what you'll get, ensuring transparency and quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610569556345,"sku":"angiodynamics-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/angiodynamics-swot-analysis.png?v=1754740245","url":"https:\/\/growthsharematrix.com\/products\/angiodynamics-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}